Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2021 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago? We need to look for any statement in the transcript that indicates an escalation in unit size of repeatable business. The transcript covers Q2 2021 earnings call. Management discusses base business recovery, COVID testing, M&A, health plan contracts, etc. Key points: They mention acquisitions, e.g., Mercy Health outreach lab services. They mention renewing Aetna contract, being preferred provider for Primark Delaware. They mention value-based programs with UnitedHealthcare and Anthem. They mention growth in health plan business. They mention new hospital lab management contracts. They mention consumer initiated testing growth. But the question is specifically about successive engagements of the same kind coming in at progressively larger size. For example, are they signing larger contracts now than before? Or are new customers starting at higher scope? Or are follow-on commitments larger? Looking at the transcript: Steve Rusckowski says "We continue to execute on our M&A strategy. In June, we announced the completion of our acquisition of an outreach laboratory services business of Mercy Health... With this acquisition we are on our way to grow our base business revenues approximately 2% from accretive strategic acquisitions this year and with additional M&A opportunities in the second half of the year." That's about M&A, but not necessarily about successive deals being larger. It's about total growth from acquisitions. They mention "We continue to grow our health plan business and made progress in the quarter with value based programs with UnitedHealthcare and Anthem. Our volumes of these health plans are growing faster than the company average." That's about volume growth, not necessarily about individual contracts being larger. They mention "During the quarter, we were also pleased to renew our longstanding contractual relationship with one of our largest health plan customers Aetna. We remain a preferred laboratory provider and partner of Aetna's network.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.